by icia icia

Objectives:
performing a comprehensive psychological, genetical and biochemical evaluation of schizophrenic patients and to evaluate the effects of enzymatic cofactors supplemented treatment on some of these parameters.

OBJECTIVES
  • performing a comprehensive psychological, genetical and biochemical evaluation of schizophrenic patients and to evaluate the effects of enzymatic cofactors supplemented treatment on some of these parameters. Thus, the project was designed as a well-defined clinical study, conducted on a distinct cathegory of psychiatric patients, aimed to fully describe the relevance of a group of biological parameters for the ethiopathogenesis of this disease: plasma homocysteine profile, corelated with human serum paraoxonase 1 activities and oxidative stress markers, several genetic polymorphisms, several life-style factors and a number of endophenotipical markers (e.g. working memory, emotional discrimination capacity etc.)
DESCRIPTION The objective of the project Schizophenotyp is to realize a clinical study orientate on the patients with specific cerebral diseases, with referral to schizophrenia. The objective of clinical study is the complete characterization of the factors involved in the schizophrenia pathology: the plasmatic homocystein profile, the activity of paraoxonazei 1 and the oxidative stress; the characterization of the genetic polymorphism and associating this to the life style (stress factors, smoking, alcohol, a sedentary life, unhealthy alimentation. At this moment there is a lot of information about the increasing level of oxidative stress in the schizophrenia pathology, on the other hand there isn’t a lot of information about the producing mechanism and its implications. A correct diet can prevent the early development of a neuro-psychic pathology that involves reactive species of oxygen (ROS) or can protect a patient that has the early stage of the diseases. In the daily diet is necessary to have folic acid and B12 vitamin for the good function of MTHFR and MS enzymes involved in the homocystein metabolism.
RESULTS ESTIMATED
  • Developing new, supplementary therapies, with products from the class of the enzymatic cofactors, having a predictable impact in improving the evolution and prevention of decompensation of the schizophrenic patients;
  • Database;
  • Centralised informatic system;
  • Questionnaires;
  • Protocol;
  • Promotional materials;
  • Scientific papers.
RESULTS OBTAINED

Stage I
Period: Oct. – Dec. 2005
Study of the importance of endophenotypic markers and genetic susceptibility in schizophrenia

The evaluation of, forms elaboration for the patient’s monitorising and the draw out the specification of data base.

 

Stage II
Period: Dec. 2005-Oct. 2006
Realization of patient lot and the initiation of treatment with enzymatic co-factors

Prelucration of biological tests.
Realization of data base.

Stage III
Period: Oct. 2006-Sep. 2007
Administration of the treatment, genetic evaluation and patient re-evaluation

The final evaluation of patients.
The implementation of the results in the data bases.

Stage IV
Period: Sep. 2007-Nov. 2007
Dissemination of results

The elaboration of articles and communications.
Web page, CD presentation of results.
Organization of an workshop.
Other Informations
Attached documents:
 ICP MS blood